The anti-HER2 agents, such as trastuzumab, pertuzumab, lapatinib, and trastuzumab emtansine (T-DM1), have dramatically improved the survival in patients with HER2-positive breast cancer (8, 9). This evidence concerns the gene ERBB2 and breast cancer.